Kent DM - Search Results

1

Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program.

Sussman JB, Kent DM, Nelson JP, Hayward RA. Sussman JB, et al. Among authors: kent dm. BMJ. 2015 Feb 19;350:h454. doi: 10.1136/bmj.h454. BMJ. 2015. PMID: 25697494 Free PMC article. Clinical Trial.

2

Treating unrelated disorders in patients with chronic disease.

Kent DM, Hayward R. Kent DM, et al. N Engl J Med. 1998 Sep 24;339(13):926; author reply 927-8. doi: 10.1056/NEJM199809243391318. N Engl J Med. 1998. PMID: 9750097 No abstract available.

3

Are randomized controlled trials sufficient evidence to guide clinical practice in type II (non-insulin-dependent) diabetes mellitus?

Vijan S, Kent DM, Hayward RA. Vijan S, et al. Among authors: kent dm. Diabetologia. 2000 Jan;43(1):125-30. doi: 10.1007/s001250050017. Diabetologia. 2000. PMID: 10672454 Free article. Review.

4

An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase.

Kent DM, Hayward RA, Griffith JL, Vijan S, Beshansky JR, Califf RM, Selker HP. Kent DM, et al. Am J Med. 2002 Aug 1;113(2):104-11. doi: 10.1016/s0002-9343(02)01160-9. Am J Med. 2002. PMID: 12133748

5

Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.

Kent DM, Vijan S, Hayward RA, Griffith JL, Beshansky JR, Selker HP. Kent DM, et al. J Clin Epidemiol. 2004 Aug;57(8):843-52. doi: 10.1016/j.jclinepi.2004.01.008. J Clin Epidemiol. 2004. PMID: 15485737

6

Reporting clinical trial results to inform providers, payers, and consumers.

Hayward RA, Kent DM, Vijan S, Hofer TP. Hayward RA, et al. Among authors: kent dm. Health Aff (Millwood). 2005 Nov-Dec;24(6):1571-81. doi: 10.1377/hlthaff.24.6.1571. Health Aff (Millwood). 2005. PMID: 16284031

7

Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis.

Hayward RA, Kent DM, Vijan S, Hofer TP. Hayward RA, et al. Among authors: kent dm. BMC Med Res Methodol. 2006 Apr 13;6:18. doi: 10.1186/1471-2288-6-18. BMC Med Res Methodol. 2006. PMID: 16613605 Free PMC article.

8

Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease.

Kent DM, Jafar TH, Hayward RA, Tighiouart H, Landa M, de Jong P, de Zeeuw D, Remuzzi G, Kamper AL, Levey AS. Kent DM, et al. J Am Soc Nephrol. 2007 Jun;18(6):1959-65. doi: 10.1681/ASN.2006101081. Epub 2007 May 2. J Am Soc Nephrol. 2007. PMID: 17475813

9

Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification.

Kent DM, Hayward RA. Kent DM, et al. JAMA. 2007 Sep 12;298(10):1209-12. doi: 10.1001/jama.298.10.1209. JAMA. 2007. PMID: 17848656 No abstract available.

10

Subgroup analyses in clinical trials.

Kent D, Hayward R. Kent D, et al. N Engl J Med. 2008 Mar 13;358(11):1199; author reply 1199-200. N Engl J Med. 2008. PMID: 18340666 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

270 results

Search Page

Filters